Abstract PR-08: Diabetes affects metabolism, redox signaling, DNA repair capacity and mutational burden in breast cancer

Author(s):  
Gatikrushna Panigrahi ◽  
Tiffany Dorsey ◽  
Wei Tang ◽  
Julian Candia ◽  
Amy Zhang ◽  
...  
2011 ◽  
Author(s):  
Jaime L. Matta ◽  
Luisa Morales ◽  
Heidi Acosta ◽  
Wanda Vargas ◽  
Michelle Colon ◽  
...  

Author(s):  
Silvia Sterpone ◽  
Tommaso Cornetta ◽  
Luca Padua ◽  
Valeria Mastellone ◽  
Daniela Giammarino ◽  
...  

2020 ◽  
Vol 21 (18) ◽  
pp. 6880
Author(s):  
Carmen Ortiz-Sánchez ◽  
Jarline Encarnación-Medina ◽  
Ralphdy Vergne ◽  
Luis Padilla ◽  
Jaime Matta

Vitamin D regulates estrogen synthesis among other mechanisms involved in breast cancer (BC) development; however, no evidence has been found regarding its relationship with DNA repair capacity (DRC). Therefore, the objective of this study was to elucidate whether DRC levels are linked with plasma 25(OH)D levels. BC cases and controls were selected from our BC cohort. DRC levels were assessed in lymphocytes through the host-cell reactivation assay. 25(OH)D levels were measured using the UniCel DxI 600 Access Immunoassay System. BC cases (n = 91) showed higher 25(OH)D levels than the controls (n = 92) (p = 0.001). When stratifying BC cases and controls into low and high DRC categories, BC cases with low DRC (n = 74) had the highest 25(OH)D levels (p = 0.0001). A positive correlation between 25(OH)D and DRC levels was found for the controls (r = 0.215, p = 0.043) while a negative correlation was found for BC cases (r = −0.236, p = 0.026). Significant differences in 25(OH)D levels were observed when stratifying by molecular subtypes (p = 0.0025). Our study provides evidence of a link between 25(OH)D and DRC in BC along with a description of to how 25(OH)D levels vary across subtypes. The positive correlation observed in the control group suggests that 25(OH)D contributes differently to DRC levels once the malignancy is developed.


2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Fatemeh Sadeghi ◽  
Marzieh Asgari ◽  
Mojdeh Matloubi ◽  
Maral Ranjbar ◽  
Nahid Karkhaneh Yousefi ◽  
...  

Abstract Background DNA repair pathways, cell cycle arrest checkpoints, and cell death induction are present in cells to process DNA damage and prevent genomic instability caused by various extrinsic and intrinsic ionizing factors. Mutations in the genes involved in these pathways enhances the ionizing radiation sensitivity, reduces the individual’s capacity to repair DNA damages, and subsequently increases susceptibility to tumorigenesis. Body BRCA1 and BRCA2 are two highly penetrant genes involved in the inherited breast cancer and contribute to different DNA damage pathways and cell cycle and apoptosis cascades. Mutations in these genes have been associated with hypersensitivity and genetic instability as well as manifesting severe radiotherapy complications in breast cancer patients. The genomic instability and DNA repair capacity of breast cancer patients with BRCA1/2 mutations have been analyzed in different studies using a variety of assays, including micronucleus assay, comet assay, chromosomal assay, colony-forming assay, γ -H2AX and 53BP1 biomarkers, and fluorescence in situ hybridization. The majority of studies confirmed the enhanced spontaneous & radiation-induced radiosensitivity of breast cancer patients compared to healthy controls. Using G2 micronucleus assay and G2 chromosomal assay, most studies have reported the lymphocyte of healthy carriers with BRCA1 mutation are hypersensitive to invitro ionizing radiation compared to non-carriers without a history of breast cancer. However, it seems this approach is not likely to be useful to distinguish the BRCA carriers from non-carrier with familial history of breast cancer. Conclusion In overall, breast cancer patients are more radiosensitive compared to healthy control; however, inconsistent results exist about the ability of current radiosensitive techniques in screening BRCA1/2 carriers or those susceptible to radiotherapy complications. Therefore, developing further radiosensitivity assay is still warranted to evaluate the DNA repair capacity of individuals with BRCA1/2 mutations and serve as a predictive factor for increased risk of cancer mainly in the relatives of breast cancer patients. Moreover, it can provide more evidence about who is susceptible to manifest severe complication after radiotherapy.


2014 ◽  
Vol 32 (2) ◽  
pp. 505-512 ◽  
Author(s):  
RAFAEL GUERRERO-PRESTON ◽  
TAL HADAR ◽  
KIMBERLY LASKIE OSTROW ◽  
ETHAN SOUDRY ◽  
MIGUEL ECHENIQUE ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document